Table 4.
Features and Treatment Outcome of High Hyperdiploid Acute Lymphoblastic Leukemia and Minimal Residual Disease at the End of Induction >0% and <5%
| High Hyperdiploid | IKZF1 | P-value | |
|---|---|---|---|
| Deleted | Wild-type | ||
| n = 333 | n = 34 | n = 299 | |
| Age | |||
| <10 | 30 (88%) | 261 (87%) | 1.00 |
| ≥10 | 4 (12%) | 38 (13%) | |
| Median (IQR) | 5.13 (3.72–6.84) | 4.00 (2.66–6.12) | 0.072 |
| Sex | 0.011 | ||
| Male | 23 (68%) | 133 (44%) | |
| Female | 11 (32%) | 166 (56%) | |
| WCC | |||
| <50 × 109/L | 31 (91%) | 247 (83%) | 0.334 |
| ≥50 × 109/L | 1 (3%) | 25 (8%) | |
| Median (IQR) | 6.65 (3.40–13.72) | 7.70 (4.10–21.50) | 0.167 |
| CNS disease | 1.00 | ||
| Yes | 0 | 1 (<0.5%) | |
| No | 15 (44%) | 128 (43%) | |
| Clinical remission | 1.00 | ||
| Yes | 34 (100%) | 299 (100%) | |
| No | 0 | 0 | |
| Induction death | 0 | 0 | |
| Ouctome | |||
| 5-y EFS | 78% (64%-94%) | 92% (89%-95%) | 0.01 |
| 5-y RR | 18% (2%-31%) | 6% (3%-9%) | 0.041 |
| 5-y OS | 88% (77%-100%) | 97% (95%-99%) | 0.041 |
| Hazard ratio EFS | 2.90 (1.20–6.80) | Reference | 0.014 |
| Follow-up in years, median (IQR) | 6.74 (4.50–8.88) | 6.69 (5.31–8.29) | |
Data are n (%), rates at 5 y (95% CI) or median (IQR).
WCC = white blood cell count; CNS = central nervous system; CI = confidence interval; EFS = event-free survival; IQR = inter-quartile range; OS = overall survival; RR = relapse rate.